JPS6413025A - Antitumoral and manufacture - Google Patents

Antitumoral and manufacture

Info

Publication number
JPS6413025A
JPS6413025A JP63134549A JP13454988A JPS6413025A JP S6413025 A JPS6413025 A JP S6413025A JP 63134549 A JP63134549 A JP 63134549A JP 13454988 A JP13454988 A JP 13454988A JP S6413025 A JPS6413025 A JP S6413025A
Authority
JP
Japan
Prior art keywords
water
amsa
reconstruction
pyroglutamic acid
medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP63134549A
Other languages
English (en)
Other versions
JPH0343251B2 (ja
Inventor
Aasaa Kapuran Maarei
Piitaa Guranatetsuku Aruhonsu
Chiyaaresu Shiineru Edowaado
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Co
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of JPS6413025A publication Critical patent/JPS6413025A/ja
Publication of JPH0343251B2 publication Critical patent/JPH0343251B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
JP63134549A 1980-06-12 1988-06-02 Antitumoral and manufacture Granted JPS6413025A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15678880A 1980-06-12 1980-06-12

Publications (2)

Publication Number Publication Date
JPS6413025A true JPS6413025A (en) 1989-01-17
JPH0343251B2 JPH0343251B2 (ja) 1991-07-01

Family

ID=22561097

Family Applications (2)

Application Number Title Priority Date Filing Date
JP8702381A Granted JPS5728006A (en) 1980-06-12 1981-06-08 Antitumoral composition
JP63134549A Granted JPS6413025A (en) 1980-06-12 1988-06-02 Antitumoral and manufacture

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP8702381A Granted JPS5728006A (en) 1980-06-12 1981-06-08 Antitumoral composition

Country Status (8)

Country Link
EP (1) EP0042553B1 (ja)
JP (2) JPS5728006A (ja)
AT (1) ATE15602T1 (ja)
AU (1) AU542346B2 (ja)
CA (1) CA1188223A (ja)
DE (1) DE3172317D1 (ja)
NZ (1) NZ197116A (ja)
ZA (1) ZA813866B (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984001506A1 (en) * 1982-10-13 1984-04-26 Univ Birmingham Pharmaceutical preparations for use in antitumour therapy
US4575509A (en) * 1983-01-31 1986-03-11 Bristol-Myers Company Water-soluble formulations of m-AMSA with pyroglutamic acid
US4626541A (en) * 1985-09-12 1986-12-02 Bristol-Myers Company Water soluble salt composition of m-AMSA
WO2020072948A1 (en) * 2018-10-04 2020-04-09 Race Oncology Ltd. Method for preparing and delivering bisantrene formulations
IL312846A (en) * 2021-11-18 2024-07-01 Onconova Therapeutics Inc Methods and preparations for the treatment of cancer
WO2024107955A1 (en) * 2022-11-17 2024-05-23 Onconova Therapeutics, Inc. Methods and compositions for treating cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010007871A (ja) * 2008-06-24 2010-01-14 Daikin Ind Ltd 換気装置

Also Published As

Publication number Publication date
AU7083781A (en) 1981-12-17
JPH0149693B2 (ja) 1989-10-25
AU542346B2 (en) 1985-02-21
JPH0343251B2 (ja) 1991-07-01
EP0042553A1 (en) 1981-12-30
JPS5728006A (en) 1982-02-15
NZ197116A (en) 1984-03-16
ZA813866B (en) 1982-06-30
CA1188223A (en) 1985-06-04
DE3172317D1 (en) 1985-10-24
EP0042553B1 (en) 1985-09-18
ATE15602T1 (de) 1985-10-15

Similar Documents

Publication Publication Date Title
IE39517L (en) Double salts of s-adenosyl-l-methionine
GB1506197A (en) Fluid in particular a hydraulic fluid comprising an antioxidant system
GR3004869T3 (ja)
GB1317075A (en) Purine nucleoside derivatives and a process for the manufacutre thereof
JPS6413025A (en) Antitumoral and manufacture
GB1440626A (ja)
ES416403A1 (es) Procedimiento de preparacion de polimeros con actividad an-tiinflamatoria.
GB1438919A (en) Compositions comprising chelated radioactive heave metals
GB1297080A (ja)
IE38641B1 (en) New pyrazolodiazepine compounds and methods for their production
ES465180A1 (es) Procedimiento para la preparacion de preparados de inmuno- globulinas
GR3004105T3 (ja)
ES486851A1 (es) Un procedimiento de preparacion de acido 3a,7b-dihidroxico- lanico
Giambra Daydreaming in males from seventeen to seventy-seven: A preliminary report.
GB1229570A (ja)
GB1202120A (en) A method of preparing comenic acid
GB1354730A (en) Process for producing trialkoxy-aluminium compounds
JPS52140496A (en) Production of nitrous oxide
FR2187312A1 (en) Rapidly-soluble paracetamol - prepd by recrystallization from aqueous dioxan
GB1295684A (ja)
JPS52111983A (en) Preparation of heparin derivatives
GB1438078A (en) Decolourization of carbonyl compounds
IL67411A0 (en) Crystalline human leukocyte interferon,its production and pharmaceutical compositions containing it
JPS51118000A (en) Production of complex phosphoric acid
ES458413A1 (es) Mejoras introducidas en un procedimiento de preparacion de -una composicion de anoxicilina sodica.